1-((2S,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1,4-dihydro-pyridine-3-carboxylic acid amide | 60531-75-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-((2S,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1,4-dihydro-pyridine-3-carboxylic acid amide
• 英文别名: 1-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-pyridine-3-carboxamide
• CAS: 60531-75-1
• 化学式: C₁₁H₁₆N₂O₅
• 分子量: 256.258
• InChiKey: MAKBMGXNXXXBFE-CDLYGTGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS<br/>[FR] DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDE ET DE NICOTINAMIDE RIBOSIDE ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS VIRALES ET DE COMPLICATIONS RESPIRATOIRES, PROVOQUÉES EN PARTICULIER PAR LE VIRUS DE LA GRIPPE OU LE CORONAVIRUS
  申请人：NUVAMID SA

  公开号：WO2021214299A1

  公开（公告）日：2021-10-28

  The present invention relates to Nicotinamide mononucleotide derivatives of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections.

  本发明涉及式(I)或(Ia)的烟酰胺单核苷酸衍生物，用于治疗和/或预防病毒感染，如呼吸道感染。本发明还涉及包含式(I)或(Ia)的化合物的制药组合物，用于治疗和/或预防病毒感染。
• NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS
  申请人：Nuvamid SA

  公开号：EP3901160A1

  公开（公告）日：2021-10-27

  The present invention relates to Nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and/or prevention of viral infections, such as respiratory infections The present invention further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.

  本发明涉及式 (I) 的烟酰胺单核苷酸衍生物 本发明还涉及用于治疗和/或预防病毒感染（如呼吸道感染）的包含式（I）化合物的药物组合物。
• COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND OTHER THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
  申请人：Nuvamid SA

  公开号：EP3949964A1

  公开（公告）日：2022-02-09

  The present disclosure relates to combinations of an active ingredient such as histamine H2 receptor antagonist and Nicotinamide mononucleotide derivatives of formula (I) or a compound of formula (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections, preferably coronavirus infections. The present disclosure further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.

  本公开涉及组胺 H2 受体拮抗剂等活性成分与式 (I) 的烟酰胺单核苷酸衍生物的组合 或式（Ia）化合物 用于治疗和/或预防病毒感染，如呼吸道感染，最好是冠状病毒感染。本公开进一步涉及包含用于治疗和/或预防病毒感染的式(I)化合物的药物组合物。
• NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS
  申请人：NUVAMID SA

  公开号：US20210332033A1

  公开（公告）日：2021-10-28

  The present disclosure relates to Nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present disclosure further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.
• COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS
  申请人：NUVAMID SA

  公开号：US20210353656A1

  公开（公告）日：2021-11-18

  The present disclosure relates to combinations of histamine H2 receptor antagonist and Nicotinamide mononucleotide derivatives of formula (I) or a compound of formula (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections, preferably coronavirus infections. The present disclosure further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.